UBS Group’s Loxo Oncology, Inc LOXO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-4,949
| Closed | -$693K | – | 8564 |
|
|
2018
Q4 | $693K | Buy |
4,949
+364
| +8% | +$55.3K | ﹤0.01% | 4004 |
|
|
2018
Q3 | $783K | Sell |
4,585
-10,740
| -70% | -$1.8M | ﹤0.01% | 4062 |
|
|
2018
Q2 | $2.66M | Sell |
15,325
-12,701
| -45% | -$1.91M | ﹤0.01% | 2898 |
|
|
2018
Q1 | $3.23M | Buy |
28,026
+15,308
| +120% | +$1.63M | ﹤0.01% | 2710 |
|
|
2017
Q4 | $1.07M | Sell |
12,718
-8,772
| -41% | -$731K | ﹤0.01% | 3728 |
|
|
2017
Q3 | $1.98M | Sell |
21,490
-12,264
| -36% | -$953K | ﹤0.01% | 3135 |
|
|
2017
Q2 | $2.71M | Buy |
33,754
+32,539
| +2,678% | +$1.8M | ﹤0.01% | 2726 |
|
|
2017
Q1 | $51K | Sell |
1,215
-66
| -5% | -$2.72K | ﹤0.01% | 5521 |
|
|
2016
Q4 | $42K | Sell |
1,281
-385
| -23% | -$9.87K | ﹤0.01% | 5968 |
|
|
2016
Q3 | $44K | Buy |
1,666
+1,181
| +244% | +$30.9K | ﹤0.01% | 5625 |
|
|
2016
Q2 | $11K | Hold |
485
| – | – | ﹤0.01% | 6748 |
|
|
2016
Q1 | $13K | Buy |
+485
| New | +$10.1K | ﹤0.01% | 6514 |
|
|
2015
Q4 | – | Sell |
-74
| Closed | -$1K | – | 8725 |
|
|
2015
Q3 | $1K | Sell |
74
-1,753
| -96% | -$34.3K | ﹤0.01% | 8281 |
|
|
2015
Q2 | $33K | Buy |
+1,827
| New | +$25K | ﹤0.01% | 6403 |
|
|
2015
Q1 | – | Sell |
-399
| Closed | -$5K | – | 9715 |
|
|
2014
Q4 | $5K | Buy |
+399
| New | +$4.65K | ﹤0.01% | 9030 |
|
Other funds holding LOXO
UBS Group's LOXO Position: Q1 2019 in Review
UBS Group sold out of Loxo Oncology, Inc (LOXO) in Q1 2019, closing a stake of 4,949 shares — an estimated $693K sold.
UBS Group first reported a position in LOXO in Q4 2014 and held it in 15 quarters. The position peaked at $3.23M in Q1 2018. 1 fund tracked by Wall St. Rank holds LOXO as of Q1 2019.
- UBS Group reported no remaining Loxo Oncology, Inc position as of Q1 2019 after selling out during the quarter.
- UBS Group sold 4,949 Loxo Oncology, Inc shares in Q1 2019, an estimated $693K.
- UBS Group first reported a position in Loxo Oncology, Inc in Q4 2014 and held it in 15 quarters.
- UBS Group's Loxo Oncology, Inc position peaked at $3.23M in Q1 2018.
- 1 fund tracked by Wall St. Rank held Loxo Oncology, Inc as of Q1 2019.
Based on UBS Group's 13F filing for Q1 2019, filed 14 May 2019.